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Abstract
Hydrogen sulfide (H2S) is a colorless, highly neurotoxic gas. It is not only an occupational and environmental hazard but also of
concern to the Department of Homeland Security for potential nefarious use. Acute high-dose H2S exposure causes death, while
survivors may develop neurological sequelae. Currently, there is no suitable antidote for treatment of acute H2S-induced neuro-
toxicity. Midazolam (MDZ), an anti-convulsant drug recommended for treatment of nerve agent intoxications, could also be of
value in treating acute H2S intoxication. In this study, we tested the hypothesis that MDZ is effective in preventing/treating acute
H2S-induced neurotoxicity. This proof-of-concept study had two objectives: to determine whether MDZ prevents/reduces H2S-
induced mortality and to test whether MDZ prevents H2S-induced neurological sequelae. MDZ (4 mg/kg) was administered IM
in mice, 5 min pre-exposure to a high concentration of H2S at 1000 ppm or 12 min post-exposure to 1000 ppm H2S followed by
30 min of continuous exposure. A separate experiment tested whether MDZ pre-treatment prevented neurological sequelae.
Endpoints monitored included assessment of clinical signs, mortality, behavioral changes, and brain histopathological changes.
MDZ significantly reduced H2S-induced lethality, seizures, knockdown, and behavioral deficits (p < 0.01). MDZ also signifi-
cantly prevented H2S-induced neurological sequelae, including weight loss, behavior deficits, neuroinflammation, and histo-
pathologic lesions (p < 0.01). Overall, our findings show thatMDZ is a promising drug for reducing H2S-induced acute mortality,
neurotoxicity, and neurological sequelae.
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Introduction
Hydrogen sulfide (H2S) is an extremely toxic gas and is only
second to carbon monoxide as a leading cause of gas-induced
deaths. It is a hazard in many occupational settings where
accidental acute high-dose exposure may occur following in-
dustrial malfunction or because of nefarious acts. Mass civil-
ian casualties of acute H2S poisoning have occurred in the past
[1, 2]. Because of its history as a chemical weapon before,
there is concern about potential misuse of H2S in acts of ter-
rorism, especially in confined spaces such as the massive
underground railroad system or in high-rise buildings [3, 4].
At high concentrations, H2S rapidly exerts its toxic effects not
only on the central nervous system but also on the respiratory
and cardiovascular systems [5, 6]. Clinical signs of acute H2S
poisoning include dyspnea, anxiety, restlessness, and ocular
and upper respiratory tract irritations in moderate concentra-
tions. Sudden collapse (Bknockdown^) accompanied by un-
consciousness, seizures, and breathing difficulty from pulmo-
nary edema, arrhythmia, and hypotension are signs of acute
exposure at higher concentrations.
Acute H2S poisoning causes high acute mortality, charac-
terized by a steep concentration-response curve. At least 50%
of H2S-induced deaths occur during exposure, while the re-
mainder of the mortality of intoxicated victims occurs within
48 h of rescue [2]. A unique characteristic of this toxic gas is
the Bknockdown^ associated with sudden exposure to high
concentrations. This is an incapacitating effect, rendering the
victims unable to escape [7]. Despite the high mortality, some
victims of acute H2S poisoning survive with or without
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supportive treatment. However, some of the survivors of acute
intoxication may develop long-term neurological sequelae
characterized by psychiatric disturbances, persistent head-
aches, sleep disorders, anxiety, memory loss, learning disor-
ders, hearing impairment, and movement disorders such as
ataxia [5, 6, 8–10]. These and other neurological sequelae
typically develop in victims who succumb to knockdown
and coma for at least 5 min, but typically for 10–15 min.
These neurological complications may or may not be perma-
nent but can be incapacitating, leading to work disability.
Currently, the exact mechanisms by which these neurological
sequelae develop are not known.
Because most deaths occur at the scene, there is a critical
need for a drug or drugs that can be used in the field for
treatment of victims of acute H2S poisoning at the site.
Currently, there is no Food and Drug Administration (FDA)
approved drug for treatment of victim of acute H2S poisoning
in the field. Currently recommended treatments of acute H2S
poisoning are of questionable efficacy and cannot be effec-
tively used in the field for treatment of mass casualties. For
example, treatment recommendations include nitrite and
hydroxocobalamin, both of which require intravenous (IV)
injections [11–14]. Intravenous injections can be challenging
to use in mass civilian victims in the field. Besides, IV nitrite
injections are associated with hypotension, a limiting side ef-
fect [1]. Also, although hydroxocobalamin binds H2S, large
volumes of IV hydroxocobalamin are recommended.
Cobinamide (Cob) is a promising experimental H2S counter-
measure that showed efficacy in animal models following
intramuscular injection [14, 15]. However, Cob has not been
approved by the FDA yet. Nitrite, hydroxocobalamin, and
cobinamide all largely work by binding H2S in vivo. Given
that H2S rapidly transmutes to the hydrosulfide ion, which in
turn is rapidly metabolized to thiosulfate and sulfate, the ther-
apeutic window for drugs that bind sulfide is very narrow [16,
17]. Consequently, there is a need to develop countermeasures
with different mechanisms of action that can easily be used in
the field for treatment of mass civilian casualties.
Midazolam (MDZ), a common benzodiazepine and an
anti-seizure medication, is on the list of The World Health
Organization most essential drugs [18]. It is available world-
wide for treatment for epilepsy and seizures and has recently
shown promise as a countermeasure against nerve agent-
induced neurotoxicity [18]. MDZ is also a powerful anxiolytic
and has sedative and amnestic properties. Due to its rapid
onset (5–10 min), relatively short half-life, and efficacy for
treatment of acute seizures and status epilepticus, MDZ is
currently being considered to replace diazepam in the strategic
defense stockpile as an anti-convulsant for nerve agent expo-
sure [18]. It is very water-soluble and therefore readily
absorbed by intramuscular (IM) injection [18]. Maximum
plasma concentration is reached in about 30 min post-IM in-
jection with > 90% bioavailability [18, 19]. MDZ has high
affinity for the benzodiazepine receptor and its anti-seizure
activity is believed to arise from its potentiation of synaptic
GABAA receptors [18]. Due to these desirable properties, we
hypothesized that MDZ is effective for treatment of acute
H2S-induced neurotoxicity by suppressing H2S-induced sei-
zure effects. This followed our previous observations in the
mouse model that deaths followed intense seizure activities
[20]. This observation is similar to that of O’Donoghue in a
pig study of acute H2S poisoning [21]. The objective of this
proof-of-concept study was to conduct a series of experiments
to test the hypothesis that MDZ is efficacious for treatment of
acute H2S-induced mortality and neurotoxicity. This is a
groundbreaking study because no prior studies have addressed
this question.
Material and Methods
Animals
All animal studies were approved by the Iowa State University
Institutional Animal Care and Use Committee (IACUC). The
7–8-week-old C57/BL6 male mice used in these studies were
purchased from The Jackson Laboratories (Bar Harbor, ME)
and weighed 20–25 g at the beginning of the experiment.
Mice were housed five per cage in the Laboratory Animal
Resource (LAR) Facility of the Iowa State University
College of Veterinary Medicine (ISU CVM, Ames, IA).
They were housed at a room temperature of 68–70 °F, relative
humidity of 35–50%, and a 12-h light/dark cycle. They were
provided 14% Protein Rodent maintenance diet (Teklad HSD
Inc., WI, USA) and drinking water ad libitum. Mice were
acclimated for 1 week prior to the start of the studies.
Experimental Approach
In this proof-of-concept study, we conducted a series of exper-
iments to evaluate the efficacy of MDZ for prophylactic treat-
ment (pre-H2S exposure) and for treatment of acute H2S ex-
posure (during exposure). Fully conscious and freely moving
mice were utilized. The mice were exposed to H2S by whole
body inhalation exposure, details of which have previously
been published [20]. Briefly, the experiments were conducted
under a chemical fume hood approved by the Environmental
Health & Safety at the ISU. H2S was introduced to the cham-
ber, and the desired concentration was achieved by dilution
with normal breathing air from a gas cylinder. The concentra-
tion of H2S in the exposure chamber was constantly monitored
using a H2S monitor (Environmental Equipment and Supply,
Harrisburg, PA) that was custom designed to measure concen-
trations of up to 1000 ppm of H2S.
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Objective 1: To Test the Efficacy of Midazolam for Reducing
H2S-Induced Acute Mortality
Experiment 1 In this experiment, we tested the hypothesis that
injectingMDZ prophylactically before a single high-dose H2S
exposure reduced mortality. Mice were injected once, either
with 0.9% saline or MDZ (4 mg/kg), IM 5 min prior exposure
to 1000 ppm H2S for 120 min (Fig. 1a). This dosage is similar
to that (0.5–10 mg/kg IM) used in experimental studies where
MDZ was investigated for treatment of seizures induced by
nerve agents in guinea pigs and rats [18].
Experiment 2 In this experiment, we tested the hypothesis that
MDZ given once during acute high-dose H2S exposure re-
duces H2S-induced mortality. Mice were exposed to
1000 ppm H2S for 12 min in the inhalation chamber, after
which mice were removed for injection of MDZ (4 mg/kg
bw) or saline (0.9%) IM. All IM injections were 50 μL in
the gastrocnemius muscle. Immediately after MDZ or saline
injection, mice were returned to the inhalation chamber for
continued exposure to H2S (1000 ppm) for 30 min. Mice were
constantly observed during exposure for clinical signs of in-
toxication using a modified functional observation battery
(FOB) [20, 22]. Specifically, seizure, knockdown, and time
of death were noted (Fig. 2a). This exposure paradigm was
done to simulate rescue from underground confined spaces or
from high-rise buildings where victim will be treated upon
arrival of first responders, which was estimated to take about
10 min, but complete evacuation may last another half an
hour. The difference is that in our model, we removed the mice
from the chamber to inject them because our exposure cham-
ber is not designed to allow safe injections to be done while
the mice are in the chamber. Mice were immediately returned
to the chamber and H2S exposure immediately resumed. This
procedure was completed within 5 min.
Objective 2: To Test the Efficacy of Midazolam for Preventing
Neurological Sequelae
In this proof-of-concept experiment, we used a MDZ/H2S
exposure paradigm summarized in Fig. 3a. Briefly, we tested
the hypothesis that MDZ administered prophylactically 5 min
Fig. 1 a Treatment paradigm to
determine the prophylactic
efficacy of MDZ. bMDZ
prevented H2S-induced mortality
by 90%. The survival data
between H2S + saline and H2S +
MDZ groups is significantly
different (p < 0.05, log-rank test,
n = 10). cMDZ prevented H2S-
induced seizure activity in mice.
The seizure data between H2S +
saline and H2S + MDZ groups is
significantly different (p < 0.05,
log-rank test, n = 10). Asterisks
(***p < 0.001) indicate statisti-
cally significant difference be-
tween H2S + saline and the H2S +
MDZ groups
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prior to H2S exposure prevents H2S-induced neurological se-
quelae. The justification for repeated short-term exposures has
been provided in prior publications [20]. Briefly, some of the
human survivors of single acute high-dose H2S poisoning
develop neurodegeneration and other neurological sequelae.
Whereas a typical exposure scenario in humans is to one large
H2S exposure leading to neurodegeneration, this approach is
characterized by very high acute mortality in mice during
exposure, with only a few of the surviving mice developing
neurodegeneration [23]. Using the single-exposure approach,
as occurs in humans, requires an unreasonably large number
of mice to test the hypothesis to achieve a statistically satis-
factory level of significance. We found that repeated short-
term acute exposures to H2S to be a more humane approach
because it is associated with lower mortality than one-time
exposure paradigm and yet yields brain lesions recapitulating
the human condition [20]. Currently, there is no other animal
model which recapitulates the H2S-induced neurodegenera-
tion following a single acute exposure by inhalation. A repeat
short-term exposure approach was also used in a monkey
study by Lund and Wieland [24]. In their study, monkeys
exposed to high doses died and only those given short-term
repeated exposures manifested lesions reminiscent of the hu-
man condition. This is the same approach we took in this and
previous studies to induce neurodegeneration in this mouse
model of H2S-induced neurodegeneration [20, 23, 25].
Mice were divided into three different groups of five male
mice as follows: Group 1 mice were injected with 0.9% saline
5 min before exposure to normal breathing air from a cylinder;
mice in Group 2 were injected with 0.9% saline 5 min prior to
exposure to 765 ppm H2S; Group 3 mice were injected with
MDZ (4 mg/kg bw) 5 min prior to exposure to 765 ppm H2S.
MDZ or 0.9% saline was injected in the rear leg
(gastrocnemius) muscle in 50 μL of solution. Normal breath-
ing air and H2S were delivered from gas cylinders. In this
acute repeated H2S exposure paradigm, on day 0, mice were
exposed to 765 ppm H2S or breathing air for 40 min post-
injection of saline orMDZ as described above. On subsequent
Fig. 2 a Treatment paradigm to
determine the efficacy of MDZ
for treatment of H2S-induced
neurotoxicity given during H2S
exposure. b Following MDZ
treatment, no more mice died
compared to about 20% survival
for saline-treated mice. The sur-
vival curve between H2S + saline
and H2S + MDZ groups is sig-
nificantly different (p < 0.0001,
log-rank test, n = 20). cMDZ
abolished H2S-induced seizure
activity in mice (n = 20).
Asterisks (*p < 0.05, **p < 0.01,
***p < 0.001) indicate statistical-
ly significant difference between
H2S + saline and the H2S + MDZ
groups
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days, the same groups ofmice were exposed either to 765 ppm
H2S or to normal breathing air for 15 min only post-injection
with 0.9% normal saline, each day for 6 days.
Objective 3: To Test the Effect of H2S on Brain Midazolam
Concentrations
During preliminary studies, we observed clinical differ-
ences between mice injected MDZ with or without expo-
sure H2S. Specifically, given equivalent dosages of
MDZ, the sleeping time of mice exposed to H2S was
longer than that of mice without exposure to H2S. We
hypothesized that high-dose acute H2S exposure causes
higher MDZ levels in brains mice exposed to H2S. In
order to test this hypothesis, two groups of mice were
exposed to 1000 ppm H2S for 20 min. They were then
removed from the inhalation for chamber for 5 min dur-
ing which mice were injected with 4 mg/kg bw midazo-
lam. Mice were then placed back in the inhalation cham-
ber for another 95 min (Fig. 6a). A breathing air group
of mice injected with saline was used as a negative con-
trol. Upon termination of H2S/breathing air exposure,
mice were removed from the chamber, immediately de-
capitated, and their brains were rapidly removed and
placed on ice. After necropsy, brain tissues were subse-
quently stored at − 80 °C until ready for analysis. For
this proof-of-concept experiment, only brain tissue was
analyzed.
Fig. 3 a Summary treatment
paradigm of H2S-induced
neurological sequelae in mice
prophylactically treated with
MDZ. bMDZ completely
prevented seizure activity and
knockdown (c) consistently
during the entire exposure period
(n = 5). Seizure and knockdown
were presented as percentage to
breathing air control group.
Seizure and knockdown data
were not statistically analyzed due
to the possibility of multiple
seizure and knockdown from
same mice during repeated
exposure to H2S. dMice exposed
to H2S and injected with saline
lost statistically significant more
weight compared to the breathing
air controls injected with saline.
MDZ prophylactically prevented
H2S-induced weight loss (n = 5).
eMDZ prevented H2S-induced
motor deficits (n = 5). Graphs are
represented as mean values.
*p < 0.05, **p < 0.001,
***p < 0.001, two-way ANOVA
followed by Bonferroni’s post-
test between H2S + saline and
H2S + MDZ groups
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Clinical Assessment
To obtain baseline data, animals were evaluated clinically and
weighed starting 3 days prior to H2S exposure. Mice were
weighed daily until euthanasia. In addition, a modified FOB
was used to evaluate clinical signs duringH2S exposure, includ-
ing knockdown, seizure activity, abnormal gait, and autonomic
function, such as urination and defecation. The same trained
observer, who conducted the study, assessed the mice through-
out the entirety of the experiment.
Behavioral Testing
For behavioral assessment, we used the VersaMax open-field
test. Behavior assessments for open-field activity were per-
formed 3 h after mice were exposed to H2S. This was per-
formed on days 2, 4, or 6 as previously described [20]. Briefly,
an automated computer-controlled device (Model RXYZCM-
16; Accuscan, Columbus, OH, USA) was used to measure the
spontaneous activity of mice in this open-field test. The di-
mensions of the activity chamber were 40 × 40 × 30.5 cm,
made of clear Plexiglas and covered with a Plexiglas lid with
holes for ventilation. Data was collected and analyzed by a
VersaMax Analyzer (Model CDA-8; AccuScan). Mice were
acclimated to the chamber 2 days before H2S exposure. On
test days, mice were placed inside the infrared monitor for
2 min to acclimate to the chamber. Open-field activities were
recorded for 10-min test sessions assessing multiple parame-
ters, including vertical activity and horizontal activity.
Histopathology and Immunohistochemistry
Mice designated for histopathologywere euthanized 24 h after
the last H2S exposure using a previously published procedure
that employed a cocktail of 100 mg/kg bw ketamine and
10 mg/kg bw xylazine given intraperitoneally [20]. Briefly,
once the micewere in a surgical plane of anesthesia, the thorax
was opened and fresh 4% paraformaldehyde solution (PFA,
pH 7.4) was injected through the left ventricle to perfuse the
animal. Thereafter, brains were post-fixed in 4% PFA for 24 h,
processed routinely, paraffin embedded, sectioned at 5 μm,
and stained with hematoxylin and eosin for routine histopa-
thology. Additional brain sections were stained using an indi-
rect immunostaining protocol (Vectastain Elite ABC kit, PK-
6101, Vector Laboratories, Inc., Burlingame, CA) that
employed primary antibodies directed against glial fibrillary
acidic protein (GFAP, ab72600, Abcam) or inducible nitric
oxide synthase (iNOS, ab15323, Abcam). Diaminobenzidine
(DAB, SK-4100, Vector Laboratories, Inc.) was used for a
chromogen. Stained sections were examined microscopically
using a Nikon Eclipse Ci-L microscope with DS-Fi2 camera.
Routine histopathology was conducted by a board-certified
veterinary pathologist blinded to the study design. The semi-
quantitative scale used for scoring the severity of lesions has
been previously published [5].
Analysis of Brain Midazolam
Whole brain tissue samples were individually minced uniformly
with scissors. A 0.1 g brain tissue sample was weighed for ex-
traction. A matrix standard curve was also prepared using 4–
0.1 g control brain tissue samples containing 0, 0.1, 1, and
10 ng MDZ. MDZ was extracted according to Bjorkman et al.
by adding 0.4 ml of 0.01 N hydrochloric acid (HCl) to each
sample. Each sample was then vortexed for 10 s and sonicated
for 5 min. A 100 μL of 0.5 N NaOHwas subsequently added to
each sample and then vortexed for 10 s. Samples were further
extracted with 0.5 ml ethyl acetate and vortexed for another 10 s.
Samples were then centrifuged at 20,000 ×g for 5 min. The top
layer of ethyl acetate was removed and placed into clean glass
vials [26]. The ethyl acetate extraction was performed twice, and
the extracts combined. The combined extracts were then dried
down under nitrogen, re-solvated in 200 μL methanol, and
vortexed for 10 s, before being quantified by LC-MS/MS, by
injection of 20 μL out of the 200 μL extract. This analysis was
performed on a Varian 310 LCMS triple quadrupole instrument
using a positive ESI with a needle voltage of (+) 3500, a shield
voltage of (+) 600, drying gas temperature of 325 °C, nebulizer
gas at 50 psi, and drying gas at 30 psi. Detection ion used was
326–290.9 with a capillary voltage of 132 and collision energy
of 21.5 V. Confirmatory ion used was 326–244 with a capillary
voltage of 132 and collision energy of 20 V. Separation was
performed on two Varian Prostar pumps equipped with a
Varian 410 autosampler using a Polaris 5 μm C-18A column
(150 × 2.0mm) at a flow rate of 0.25mL/min. Themobile phase
contained 60%10mMammonium acetate and 0.1% formic acid
in methanol and 40% 0.1% formic acid. Retention time of the
MDZ was 3.5 min [27, 28]. All samples were quantified against
the matrix standard curve.
Data Analyses
Data are presented as mean and standard error of the mean.
Clinical toxicity during exposures was analyzed using linear
regression. Survival and seizure curve data were analyzed
using log-rank test. Fisher’s Exact Test for Count Data was
used for proportional count analysis for each time point be-
tween H2S + Saline and H2S + MDZ groups. Body weight
change and behavioral test data were analyzed using two-way
ANOVA followed by a Bonferroni’s post-test. MDZ concen-
tration data were analyzed using one-way ANOVA.
Histopathology scores were analyzed using a Student’s t test
comparing the H2S and saline-treated mice to the H2S and
midazolam-treated mice. ANOVA tests and log-rank test were
performed on Prism version 6 (GraphPad Prism Software, La
Jolla, CA). Fisher’s Exact Tests for Count Data were
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performed using R software version 3. 3. 2 (https://www.r-
project.org/). Data was considered statistically significant
when the p value is lower than 0.05.
Results
Objective 1: Midazolam Prevented H2S-Induced
Mortality
Experiment 1 This experiment evaluated the efficacy of MDZ
given pre-exposure to H2S. In this study, 100% of mice
injected with saline and exposed to H2S experienced seizures
and died (Fig. 1b–c). In contrast, in the group of mice
pretreated with midazolam, only 10% mortality was observed
at the 2 h time point when the experiment was terminated,
with none of these mice experiencing seizures (Fig. 1b–c).
Experiment 2 This study evaluated the efficacy of MDZ given
during exposure to a single acute high dose of H2S. All of the
mice exposed to breathing air and injected with 0.9% normal
saline survived. Compared to this group, only 25% of mice
exposed to H2S and injected 0.9% normal saline survived
(Fig. 2b). H2S-induced mortality was time- and concentra-
tion-dependent. However, in the group of mice exposed to
H2S and treated with MDZ, the survival rate was 100%, indi-
cating treatment with MDZ significant prevented mortality
from H2S-induced toxicity (Fig. 2a). Furthermore, none of
the H2S-exposed mice treated with MDZ manifested seizure
activity compared to 90% in the H2S/saline group (Fig. 2c).
Objective 2: Midazolam Prevented H2S-Induced
Neurodegeneration and Neurotoxicity
Control mice exposed to breathing air and treated with saline
were completely normal for the entire duration of the study.
DuringH2S exposure, mice pretreatedwithMDZ and exposed
to H2S were clinically healthy compared to mice treated with
saline. Specifically, saline pre-treated mice and exposed to
H2S exhibited lacrimation, salivation, ataxia, impaired
righting reflex (knockdown), and convulsions which were ab-
sent in mice pre-treated with MDZ. We considered mice in
lateral recumbence with inability to right self as experiencing
knockdown. Mice in knockdown could separately and dis-
tinctly manifest seizure activities on and off with continued
H2S exposure. None of the mice pre-treated with MDZ man-
ifested any seizures or knockdowns (Fig. 3b–c). However,
MDZ-treated mice were less active and preferred to remain
sedentary. MDZ also significantly prevented H2S-induced
weight loss (Fig. 3d). The weights of mice from H2S/MDZ
group were statistically similar to those of the saline/H2S
group.
In the open-field test, mice pre-treatedwithMDZ performed
statistically significantly better overall than mice in the saline/
H2S group on all days of testing. The vertical and horizontal
activities of mice pre-treated with MDZ were better by 55% or
greater compared to the H2S and saline group (Fig. 3e).
Without MDZ pre-treatment, exposure to H2S consistently
induced severe necrotic lesions in the inferior colliculus and
thalamus, often with mild or moderate hemorrhage (Fig. 4a,b).
Microscopically, the inferior colliculus of H2S-exposed mice
showed extensive vacuolization of the neuropil, degeneration
or loss of neurons, scattered apoptotic cell debris, influx and
activation of microglia and astrocytes, and foci of hemorrhage
in some animals. Pre-treatment withMDZmarkedly reduced the
incidence and severity of these neurologic lesions. The most
consistent changes observed in the inferior colliculus or thalami
of MDZ-treated mice were minimal to mild enlargement and
prominence of microglial nuclei and vacuolization of the
neuropil. Lesions were not observed in animals exposed to
breathing air. Subjective assessment of intensity and distribution
of immunopositivity in GFAP- and iNOS-immunostained sec-
tions revealed moderately increased expression of GFAP and
iNOS in untreated, H2S-exposed mice and minimal to mildly
increased GFAP and iNOS in MDZ-treated animals (Fig. 5).
Objective 3: H2S Affects Brain Midazolam
Concentration
This experiment evaluated the effect of H2S on MDZ brain
concentration. We measured MDZ in brain tissue and found
that mice exposed to breathing air and injected with MDZ had
significantly less MDZ concentration in the brain than mice
which were injected with MDZ and exposed to H2S (Fig. 6).
Discussion
H2S is a rapidly acting, highly neurotoxic gas, with high acute
mortality, usually at the scene of exposure. Currently, there is a
need for drugs for treatment of victims of acute H2S intoxication
in the field [7, 29]. This seminal proof-of-concept study has
shown that prophylactic treatment with MDZ before H2S expo-
sure and treatment withMDZ during H2S exposure significantly
increases survival in mice exposed to lethal concentrations of
H2S. The study also shows that prophylactic treatment with
MDZ prevents H2S-induced neurodegeneration and neurologi-
cal sequelae. These preliminary findings are significant consid-
ering that there is no FDA-approved drug with such properties
for treatment of H2S poisoning now currently on the market.
The exact mechanism(s) by which MDZ was able to in-
crease survival and to reduce neurodegeneration is/are not
known and is beyond the objectives of this concept study. It
is likely counteracting one or more of the effects of H2S-in-
duced neurotoxicity. Inhibition of Complex IV in cytochrome
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c oxidase resulting in reduced ATP is a well-established mech-
anism of H2S-induced toxicity [15]. H2S also causes oxidative
stress via generation of reactive oxygen and sulfur-free radi-
cals [30, 31]. H2S also causes neurotoxicity by increasing
concentrations of biogenic amines [20]. In this mouse model
of H2S-induced neurotoxicity, we have previously reported
that lethality was associated with increased seizure activity
[20]. Mortality was also previously associated with seizures
in a pig study [21]. Consequently, we hypothesized that sup-
pression of seizures by MDZ increases survival in H2S-intox-
icated mice. Results of this proof-of-principle study indicate
that our hypothesis is correct. However, identifying which of
the above neurotoxic mechanisms of H2S are antagonized by
MDZ is beyond the objectives of this study. We hypothesize
that, MDZ, an anti-convulsant drug, likely works by quieting
neuronal activity through GABAA receptors. MDZ potentiates
GABAA receptors, inhibiting excitability [18]. However,
MDZ has also been shown to counteract oxidative stress [32,
33]. Specific mechanisms involved will be evaluated in future
studies. MDZ is appealing because it can be given easily in the
field for treatment of mass civilian victims of acute H2S poi-
soning IM by an autoinjector similar to an EpiPen®.
Until now, other therapeutics being evaluated or recom-
mended for treatment of acute H2S poisoning, including nitrite
Fig. 4 Photomicrographs of
lesions in the thalamus and
inferior colliculus of mice
prophylactically treated with
MDZ prior to H2S. Note the
pallor and loss of neurons in the
thalamus of the saline/H2S-
exposed mouse. Note that brain
tissue of the H2S + MDZ group is
similar to that of the breathing
air + saline group. Severe changes
in the inferior colliculus of the
H2S + saline-exposed mice
include marked vacuolization of
the neuropil, degeneration and
loss of neurons, and prominent
glial response. Graphs are
represented as mean values.
Asterisks (****p < 0.0001,
***p < 0.001) indicate a
significant difference between
H2S + saline and the H2S + MDZ
groups
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and hydroxocobalamin, work by binding H2S in vivo.
Treatments that bind sulfides have a disadvantage because
H2S rapidly dissociates into daughter sulfide species almost
instantaneously in vivo. For example, at the normal pH of 7.4,
H2S dissociates 2:1 into hydrosulfide anion:undissociated
H2S which exist in a dynamic at this ratio [15]. Furthermore,
H2S is rapidly metabolized in the liver and kidney to thiosul-
fate and sulfate. It has been reported that 70% of H2S is me-
tabolized to sulfate within 15 min [17]. Optimal efficacy of
such drugs occurs when H2S is still available to scavengers. It
is not surprising, therefore, that the efficacy of nitrite for treat-
ment of sulfide toxicity is questioned [5]. Besides, both nitrite
and hydroxocobalamin have to be given IV, a route not con-
venient for treatment of mass civilian casualties. MDZ, which
is well-absorbed by IM route, acts rapidly [18, 19]. For exam-
ple, in models of nerve agent intoxications, peak efficacy has
been reported to occur within 10 min of IM injection [18].
MDZ also has the added advantage that it is currently ap-
proved as an anti-convulsant drug and is currently being con-
sidered for inclusion in the strategic defense stockpile for
treatment of chemical-induced seizures, including nerve
agents. Given the promising preliminary results, repurposing
MDZ for acute treatment of acute H2S poisoning is attractive.
Considering it is already approved for human use, should it
prove safe for treatment of acute H2S intoxication, it will like-
ly be brought to market much faster.
This preliminary data is encouraging because MDZ has
significant potential for field application. For example, pro-
phylactic treatment with MDZ could be an option for first
responders before attempted rescue, as an added layer of se-
curity. Currently, first responders use self-contained breathing
apparatus in rescuemissions to avoid intoxication. Sometimes,
these get dislodged and first responders get exposed to H2S
[34, 35]. Given in appropriate doses which do not impair judg-
ment or cognitive abilities in first responders, MDZ could
potentially serve as an added layer of protection. However,
such limitations are of less concern for treatment of civilian
victims of acute H2S poisoning during or after H2S exposure.
The rapid absorption of MDZ following IM injection is
particularly appealing, especially for field treatment of mass
civilian casualties during accidents or terrorist acts. Persistent
convulsions are one of the sequelae reported in severely affect-
ed victims of acute H2S poisoning. MDZ may potentially be
useful for post-H2S exposure treatment in such patients. The
ability of MDZ to prevent mortality when given before or
during H2S exposure, as shown in this study, is phenomenal.
Fig. 5 Representative
photomicrographs of
immunohistochemical staining of
the inferior colliculus
demonstrating expression of glial
fibrillary acidic protein (GFAP), a
marker of astrocyte activation,
and inducible nitric oxide
synthase (iNOS), a marker for
neuroinflammation. Note the
increased expression of GFAP
and iNOS (brown chromogen
deposition) in the brain of the
saline/H2S group, while levels of
these markers in the brains of
MDZ-treated animals have less
immunostaining, suggesting less
inflammation the MDZ-treated
group
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Besides increasing survival, MDZ also significantly reduced
H2S-induced neurodegeneration and resulted in improved be-
havioral performance. We also found that MDZ pre-treatment
consistently prevented knockdown and seizures induced by
high-dose acute exposures to H2S. The fact that MDZ pretreat-
ment prophylactically prevented loss in body weight also sug-
gests that these mice were clinically better than saline-treated
control mice. It will be interesting in future studies to investi-
gate whether post-H2S treatment with MDZ also affords pro-
tection and increases survival and/or reduces neurodegenera-
tion and improves behavioral performance.
Histologic lesions observed in the brains of untreated ani-
mals exposed to H2S are consistent with those observed in our
previous studies using a mouse inhalation model of H2S expo-
sure that generates severe lesions and are similar to those re-
ported in human patients [20]. Pre-treatment with MDZ re-
duced the development and severity of histologic lesions, rein-
forcing the clinical and behavioral observations in these mice.
Reduced induction of GFAP and iNOS, markers of astrocyte
activation and inflammation, respectively, in animals that were
prophylactically pre-treated withMDZ supports the notion that
MDZ prevents the induction of an astroglial response and ac-
tivation of inflammatory pathways. We have previously shown
that inflammation plays a role in H2S-induced neurotoxicity
[20]. The mechanism(s) of action by which prophylactic treat-
ment with MDZ reduced mortality and neurodegeneration is/
are not known and cannot be ascertained from this limited
proof-of concept study. However, it has been reported that
MDZ reduces seizure activity by binding to the GABAA re-
ceptors leading to allosteric potentiation of GABA-gated hy-
perpolarization of the cell, inhibiting excitability [18].
Although not determined for H2S, seizure activity has been
linked to neurodegeneration following nerve agent exposure
[36]. Reduced seizure activity is potentially one of the mecha-
nisms by which MDZ was neuroprotective in this study.
MDZ has also been used for treatment of critically ill pa-
tients suffering from pathologic effects of oxidative stress,
such as infection, hemodynamic instability, and hypoxia
[33]. H2S-induced neurotoxicity is characterized by hemody-
namic instability (hypotension) and hypoxia [37, 38]. H2S-
induced neurotoxicity is also characterized by oxidative stress
[5, 15]. There is evidence supporting the inverse correlation
between MDZ and reactive oxygen species [33]. MDZ has
been shown to interfere with the synthesis and release of nitric
oxide and tumor necrosis factor-alpha [33]. MDZ also exerts
protective effects during oxidative stress through the activa-
tion of Protein Kinase B (Akt) via phosphorylation in neuro-
nal cells. Akt phosphorylation plays an important role in cell
proliferation and cell survival [32, 33]. Potentially, these are
some of the mechanisms worthy of investigating in future
experiments designed to define neuroprotective mechanisms
of acute H2S poisoning in this animal model.
Fig. 6 MDZ concentration in the
brain. Note the significantly
higher MDZ concentration in
mice exposed to high
concentration of H2S compared to
those without H2S exposure.
Graphs are represented as mean
values. ****p < 0.0001, ANOVA
followed by Bonferroni’s post-
test between H2S + MDZ and the
breathing air + MDZ group
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Another interesting finding from this study is the potential
interaction between H2S and MDZ. Exposure to lethal con-
centration of H2S increased brain MDZ concentration. The
reasons(s) for this finding are not clear and cannot be deter-
mined from this study; but either H2S increased penetration of
MDZ in the brain or it impairedMDZmetabolism in the brain.
Whatever the reason, this finding has practical implications.
Dose-response MDZ studies are needed to identify an ideal
therapeutic dose. In this study, we chose to use 4 mg/kg bw
based on results of preliminary studies and because this mouse
dosage is almost equivalent to the human dosage of 0.33 mg/
kg bw corrected for surface area [39]. The recommended dose
in adults is two 10 mg ChemPack MDZ auto-injectors, which
for a 60 kg person is equivalent to 0.33 mg/kg.
This initial proof-of-concept study has some limitations. A
lot more work lies ahead before MDZ can be recommended
for treatment of human victims of acute H2S poisoning.
Among the limitations, this was an exploratory study, and
data was collected using a small number of animals and only
using one species and sex—male mice. It will be helpful to
repeat this study with a large number of mice of both sexes. It
will also be necessary to repeat the study in a non-rodent spe-
cies because species differences between humans and experi-
mental animals exist. Showing efficacy in more than one spe-
cies will increase confidence in results reported here. Also,
although results of prophylactic pretreatment with MZD have
relevance for first responders, a major need is to rigorously
evaluate the efficacy of MDZ for treatment of civilian victims
of H2S poisoning in the field. To this end, preliminary results
showing increased survival, reduced seizure activity, and re-
duced knockdown in mice injected with MDZ during H2S ex-
posure are very encouraging. This is particularly so because
H2S-induced acute toxicity is uniquely characterized by a steep
dose-response curve with high mortality during or soon after
exposure as a major outcome. More research is needed to con-
clusively determine the efficacy ofMDZ given during exposure
and to evaluate its efficacy given post-H2S exposure, because
this is what is most relevant for civilian use. Another limitation
is that this study involved only one MDZ dosage. Appropriate
dose-responseMDZ studies need to be done to choose a dosage
that is not only efficacious but also safe and with minimal side
effects. MDZ is rapidly and well-absorbed trans-nasally and via
the sublingual routes [40, 41]. Future studies will test the effi-
cacy of MDZ given via these routes. The advantage of these
routes is that they bypass the liver and are potentially Bdose-
saving^ compared to the IM route and likely will be associated
with fewer side effects, if any. Both sublingual and trans-nasal
routes are also very attractive for field treatment of civilian
casualties as they are easily accessible.
In summary, in this mouse model, MDZ treatment reduced
mortality, seizure activity, and behavioral deficits and was neu-
roprotective against H2S-induced neurotoxicity. Results of this
proof-of-concept study also revealed potential interaction
between acute H2S exposure and MDZ because brain MDZ
concentrations were significantly higher in H2S-exposed mice
than those that were not.We acknowledge the limitations of this
single study. However, results of this study strongly suggest that
MDZ is a promising novel drug candidate for treatment of acute
H2S-induced neurotoxicity and neurodegeneration. Noted ben-
efits of MDZ of reduced acute mortality, reduced seizures, and
knockdown given during H2S exposure are very appealing, and
further research is recommended to test the efficacy ofMDZ for
treatment of acute H2S intoxication and for understanding its
mechanisms of action against H2S-induced neurotoxicity.
Acknowledgements We thank Dr. Jacek Koziel for setting up the inha-
lation chamber and Patricia Lewis for histology. We thank Dr. Chong
Wang and Mr. Dae-Gyu Jang for helping statistical analyses of data.
Funding This research was funded by the Iowa State University internal
salary savings and incentive account funds.
Compliance with Ethical Standards
Conflict of Interest All authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. McCabe LC, Clayton GD. Air pollution by hydrogen sulfide in
Poza Rica, Mexico; an evaluation of the incident of Nov. 24,
1950. AMA archives of industrial hygiene and occupational med-
icine. 1952;6(3):199–213.
2. Yang D, Chen G, Zhang R. Estimated public health exposure to
H2S emissions from a sour gas well blowout in Kaixian County,
China. Aerosol Air Qual Res. 2006;6(4):430–43. https://doi.org/10.
4209/aaqr.2006.09.0018.
3. DHS. Federal register. 1997;72(223):65423.
4. DHS. Appendix A: chemicals of interest list. In: Federal register:
Department of Homeland Security; 2007. 2017.
5. Rumbeiha W, Whitley E, Anantharam P, Kim DS, Kanthasamy A.
Acute hydrogen sulfide-induced neuropathology and neurological
sequelae: challenges for translational neuroprotective research. Ann
N Y Acad Sci. 2016;1378(1):5–16. https://doi.org/10.1111/nyas.
13148.
6. Arnold IM,DufresneRM,AlleyneBC, Stuart PJ. Health implication of
occupational exposures to hydrogen sulfide. J OccupMed. 1985;27(5):
373–6. https://doi.org/10.1097/00043764-198505000-00018.
7. Guidotti TL. Hydrogen sulfide intoxication. Handb Clin
Neurol. 2015;131:111–33. https://doi.org/10.1016/B978-0-
444-62627-1.00008-1.
8. Snyder JW, Safir EF, Summerville GP, Middleberg RA.
Occupational fatality and persistent neurological sequelae after
mass exposure to hydrogen sulfide. Am J Emerg Med.
1995;13(2):199–203. https://doi.org/10.1016/0735-6757(95)
90094-2.
J. Med. Toxicol. (2018) 14:79–90 89
9. Matsuo M, Cummins JW, Anderson RE. Neurological sequelae of
massive hydrogen sulfide inhalation. Arch Neurol. 1979;36(7):
451–2. https://doi.org/10.1001/archneur.1979.00500430081019.
10. Tvedt B, Skyberg K, Aaserud O, Hobbesland A, Mathiesen T.
Brain damage caused by hydrogen sulfide: a follow-up study of
six patients. Am J Ind Med. 1991;20(1):91–101. https://doi.org/
10.1002/ajim.4700200109.
11. Hall AH, Rumack BH. Hydrogen sulfide poisoning: an antidotal
role for sodium nitrite? Vet Hum Toxicol. 1997;39(3):152–4.
12. Cronican AA, Frawley KL, Ahmed H, Pearce LL, Peterson J.
Antagonism of acute sulfide poisoning in mice by nitrite anion
without methemoglobinemia. Chem Res Toxicol. 2015;28(7):
1398–408. https://doi.org/10.1021/acs.chemrestox.5b00015.
13. Hoidal CR, Hall AH, Robinson MD, Kulig K, Rumack BH.
Hydrogen sulfide poisoning from toxic inhalations of roofing as-
phalt fumes. Ann Emerg Med. 1986;15(7):826–30. https://doi.org/
10.1016/S0196-0644(86)80383-3.
14. Bebarta VS, Garrett N, Brenner M, Mahon S, Maddry JK,
Boudreau S, et al. Efficacy of intravenous cobinamide versus
hydroxocobalamin or saline for treatment of severe hydrogen sul-
fide toxicity in a swine (Sus Scrofa) model. Acad Emerg Med.
2017;24(9):1088–98. https://doi.org/10.1111/acem.13213.
15. Jiang J, Chan A, Ali S, Saha A, Haushalter KJ, Lam WL, et al.
Hydrogen sulfide-mechanisms of toxicity and development of an
antidote. Sci Rep. 2016;6(1):20831. https://doi.org/10.1038/
srep20831.
16. Beauchamp RO, Jr., Bus JS, Popp JA, Boreiko CJ, Andjelkovich
DA. A critical review of the literature on hydrogen sulfide toxicity.
Crit Rev Toxicol 1984;13(1):25–97. doi:https://doi.org/10.3109/
10408448409029321.
17. Strickland J, Cummings A, Spinnato III JA, Liccione JJ, Foureman
GL. Toxicological review of hydrogen sulfide. Washington, DC:
U.S. Environmental Protection Agency; 2003. https://cfpub.epa.
gov/ncea/iris/iris_documents/documents/toxreviews/0061tr.pdf.
Accessed 28 Dec 2017
18. Reddy SD, Reddy DS.Midazolam as an anticonvulsant antidote for
organophosphate intoxication—a pharmacotherapeutic appraisal.
Epilepsia. 2015;56(6):813–21. https://doi.org/10.1111/epi.12989.
19. Levy A, Kushnir M, Chapman S, Brandeis R, Teitelbaum Z, Gilat
E. Characterization of early plasma concentrations of midazolam in
pigs after administration by an autoinjector. Biopharm Drug
Dispos. 2004;25(7):297–301. https://doi.org/10.1002/bdd.417.
20. Anantharam P, Whitley EM, Mahama B, Kim DS, Imerman PM,
Shao D, et al. Characterizing a mouse model for evaluation of
countermeasures against hydrogen sulfide-induced neurotoxicity
and neurological sequelae. Ann N YAcad Sci. 2017;1400(1):46–
64. https://doi.org/10.1111/nyas.13419.
21. O'Donoghue JG. Hydrogen sulphide poisoning in swine. Canadian
Journal of Comparative Medicine and Veterinary Science.
1961;25(9):217–9.
22. McDaniel KL, Moser VC. Utility of a neurobehavioral screening
battery for differentiating the effects of two pyrethroids, permethrin
and cypermethrin. Neurotoxicol Teratol. 1993;15(2):71–83. https://
doi.org/10.1016/0892-0362(93)90065-V.
23. Anantharam P,Whitley EM,MahamaB, KimD-S, Sarkar S, Santana
C, et al. Cobinamide is effective for treatment of hydrogen sulfide-
induced neurological sequelae in a mouse model. Ann N YAcad Sci.
2017;1408(1):61–78. https://doi.org/10.1111/nyas.13559.
24. Lund OE, Wieland H. Pathologic-anatomic findings in experimen-
tal hydrogen sulfide poisoning (H2S). A study on rhesus monkeys.
Internationales Archiv fur Arbeitsmedizin. 1966;22(1):46–54.
25. Rumbeiha W, Whitley E, Anantharam P, Kim DS, Kanthasamy A.
Acute hydrogen sulfide-induced neuropathology and neurological se-
quelae: challenges for translational neuroprotective research. Ann N Y
Acad Sci. 2016;1378(1):5–16. https://doi.org/10.1111/nyas.13148.
26. Bjorkman S, Fyge A, Qi Z. Determination of the steady state tissue
distribution of midazolam in the rat. J Pharm Sci. 1996;85(8):887–
9. https://doi.org/10.1021/js960113+.
27. Link B, Haschke M, Wenk M, Krahenbuhl S. Determination of
midazolam and its hydroxy metabolites in human plasma and oral
fluid by liquid chromatography/electrospray ionization ion trap tan-
dem mass spectrometry. Rapid Commun Mass Spectrom.
2007;21(9):1531–40. https://doi.org/10.1002/rcm.2987.
28. Lepper ER, Hicks JK, Verweij J, Zhai S, Figg WD, Sparreboom A.
Determination of midazolam in human plasma by liquid chroma-
tography with mass-spectrometric detection. J Chromatogr B
Analyt Technol Biomed Life Sci. 2004;806(2):305–10. https://doi.
org/10.1016/j.jchromb.2004.04.003.
29. Guidotti TL. Hydrogen sulfide: advances in understanding human
toxicity. Int J Toxicol. 2010;29(6):569–81. https://doi.org/10.1177/
1091581810384882.
30. Truong DH, Eghbal MA, Hindmarsh W, Roth SH, O'Brien PJ.
Molecular mechanisms of hydrogen sulfide toxicity. Drug Metab
Rev. 2006 ;38 (4 ) : 733–44 . h t t p s : / / do i . o rg / 10 . 1080 /
03602530600959607.
31. Truong DH, Mihajlovic A, Gunness P, Hindmarsh W, O'Brien PJ.
Prevention of hydrogen sulfide (H2S)-induced mouse lethality and
cytotoxicity by hydroxocobalamin (vitamin B(12a)). Toxicology.
2007;242(1–3):16–22. https://doi.org/10.1016/j.tox.2007.09.009.
32. Han C, Ding W, Jiang W, Chen YU, Hang D, Gu D, et al. A
comparison of the effects of midazolam, propofol and
dexmedetomidine on the antioxidant system: a randomized trial.
Experimental and Therapeutic Medicine. 2015;9(6):2293–8.
https://doi.org/10.3892/etm.2015.2410.
33. Chong WS, Hyun CL, Park MK, Park JM, Song HO, Park T, et al.
Midazolam protects B35 neuroblastoma cells through Akt-
phosphorylation in reactive oxygen species derived cellular injury.
Korean Journal of Anesthesiology. 2012;62(2):166–71. https://doi.
org/10.4097/kjae.2012.62.2.166.
34. Anderson AR. Characterization of chemical suicides in the United
States and its adverse impact on responders and bystanders. West J
Emerg Med. 2016;17(6):680–3. https://doi.org/10.5811/westjem.
2016.9.32267.
35. Ruder JB, Ward JG, Taylor S, Giles K, Higgins T, Haan JM.
Hydrogen sulfide suicide: a new trend and threat to healthcare pro-
viders. J Burn Care Res. 2015;36(2):e23–5. https://doi.org/10.
1097/BCR.0000000000000065.
36. Hobson BA, Siso S, Rowland DJ, Harvey DJ, Bruun DA, Garbow
JR, et al. Magnetic resonance imaging reveals progressive brain
injury in rats acutely intoxicated with diisopropylfluorophosphate.
Toxicol Sci. 2017;157(2):342–53. https://doi.org/10.1093/toxsci/
kfx049.
37. Gerasimon G, Bennett S, Musser J, Rinard J. Acute hydrogen sul-
fide poisoning in a dairy farmer. Clin Toxicol (Phila). 2007;45(4):
420–3. https://doi.org/10.1080/15563650601118010.
38. Milby TH, Baselt RC. Hydrogen sulfide poisoning: clarification of
some controversial issues. Am J Ind Med. 1999;35(2):192–5.
https://doi.org/10.1002/(SICI)1097-0274(199902)35:2<192::AID-
AJIM11>3.0.CO;2-C.
39. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal
to human studies revisited. FASEB J. 2008;22(3):659–61. https://
doi.org/10.1096/fj.07-9574LSF.
40. Scott RC, Besag FM, Boyd SG, Berry D, Neville BG. Buccal ab-
sorption of midazolam: pharmacokinetics and EEG pharmacody-
namics. Epilepsia. 1998;39(3):290–4. https://doi.org/10.1111/j.
1528-1157.1998.tb01375.x.
41. Santangelo B, Micieli F, Marino F, Reynaud F, Cassandro P,
Carfora A, et al. Plasma concentrations and sedative effects of a
dexmedetomidine, midazolam, and butorphanol combination after
transnasal administration in healthy rabbits. J Vet Pharmacol Ther.
2016;39(4):408–11. https://doi.org/10.1111/jvp.12282.
90 J. Med. Toxicol. (2018) 14:79–90
